Guideline

Ascletis Announces Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/ GANOVO® Regimen, an All-oral Direct Anti-HCV Therapy

Friday, December 3, 2021 - 4:05am

HANGZHOU, China and SHAOXING, China, Dec. 2, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that its all-oral direct anti-hepatitis C virus (HCV) ASCLEVIR® (Ravidasvir)/ GANOVO® (Danoprevir) regimen has been included in the Medicine Catalog for National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2021) (《国家基本医疗保险、工伤保险和生育保险药品目录(2021)年》) (the "National Reimbursement Drug List" or the "NRDL"). 

Key Points: 
  • The results from the Phase II/III clinical trials in China with the all-oral direct anti-HCV ASCLEVIR / GANOVO regimen showed a 99% cure rate in genotype 1 non-cirrhosis HCV patients.
  • ASCLEVIR is a pan-genotypic NS5Ainhibitor with high genetic barrier to resistance, with a cure rate of 100% in patients with baseline NS5Aresistance.
  • "The assessment by National Healthcare Security Administration ("NHSA") is based on multi-factors including efficacy, safety, economy, novelty and fairness.
  • Ascletis will continue to support the country's healthcare system and contributes to the national 'Healthy China' strategy."

DGAP-News: Adrenomed Receives Positive EMA Scientific Advice for Further Clinical Development of Adrecizumab in Septic Shock

Thursday, December 2, 2021 - 11:03am

In its scientific advice, EMA supports Adrenomed's strategy to continue the development of Adrecizumab based on the completed Phase II trial AdrenOSS-2, which demonstrated favorable safety and tolerability and a positive survival trend.

Key Points: 
  • In its scientific advice, EMA supports Adrenomed's strategy to continue the development of Adrecizumab based on the completed Phase II trial AdrenOSS-2, which demonstrated favorable safety and tolerability and a positive survival trend.
  • The planned pivotal trial is a biomarker-guided, multiregional, randomized, placebo-controlled study reflecting the precision medicine approach Adrenomed is pursuing with Adrecizumab.
  • The trial will investigate Adrecizumab on top of standard of care in the treatment of intensive care unit (ICU) patients with early septic shock.
  • The scientific advice strongly supports our plans and helps to pave the way for the further development of Adrecizumab."

SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health

Friday, November 26, 2021 - 9:26am

With the theme of "Shaping a Resilient and Sustainable Future", the Inaugural ASGH was held at the Convention Hall of Hong Kong Convention and Exhibition Centre and synchronized online.

Key Points: 
  • With the theme of "Shaping a Resilient and Sustainable Future", the Inaugural ASGH was held at the Convention Hall of Hong Kong Convention and Exhibition Centre and synchronized online.
  • Doing innovative research in Hong Kong enjoys advantages such as legal protection and patenting system, which will facilitate the companies to get licensed with other collaborators.
  • Dr. Shui On LEUNG said, "It is a great honour to attend the Inaugural ASGH on behalf of the Company.
  • SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases.

Société du Grand Paris : final terms serie 17 Issue of EUR 1,250,000,000 1.000 per cent. Notes due 26 November 2051

Thursday, November 25, 2021 - 2:04pm

Socit du Grand Paris : final terms serie 17 Issue of EUR 1,250,000,000 1.000 per cent.

Key Points: 
  • Socit du Grand Paris : final terms serie 17 Issue of EUR 1,250,000,000 1.000 per cent.
  • Notes due 26 November 2051
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • This document constitutes the Final Terms of the Notes described herein for the purposes of the Prospectus Regulation and must be read in conjunction with such Base Prospectus.
  • The Final Terms and the Base Prospectus will be available on the Issuer's website ( https://www.societedugrandparis.fr/publications-financieres-1870 ) and on the AMF's website ( www.amf-france.org ).

Société du Grand Paris : Final terms - Issue of EUR 1,750,000,000 0.300 per cent. Notes due 25 November 2031

Thursday, November 25, 2021 - 2:04pm

Socit du Grand Paris : Final terms - Issue of EUR 1,750,000,000 0.300 per cent.

Key Points: 
  • Socit du Grand Paris : Final terms - Issue of EUR 1,750,000,000 0.300 per cent.
  • Notes due 25 November 2031
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • This document constitutes the Final Terms of the Notes described herein for the purposes of the Prospectus Regulation and must be read in conjunction with such Base Prospectus.
  • The Final Terms and the Base Prospectus will be available on the Issuer's website ( https://www.societedugrandparis.fr/publications-financieres-1870 ) and on the AMF's website ( www.amf-france.org ).

NCLA Amicus Brief Backs Cert Petition Challenging Deference to Sentencing Guidelines Commentary

Wednesday, November 24, 2021 - 4:47pm

Under the current deference regime, district courts in seven circuits systematically violate the due-process rights of thousands of criminal defendants by applying Stinson deference to increase the Sentencing Guideline range beyond what Congress approved.

Key Points: 
  • Under the current deference regime, district courts in seven circuits systematically violate the due-process rights of thousands of criminal defendants by applying Stinson deference to increase the Sentencing Guideline range beyond what Congress approved.
  • Following the Courts decision in Stinson, however, the circuit courts of appeals began to give disproportionate weight to the Commissions commentary whenever the Sentencing Guidelines plain text was at all ambiguous.
  • petition on behalf of client Marcus Broadway asking the Court to consider this issue in Marcus Broadway v. United States .
  • Mr. Wynns petition presents the Supreme Court a critical opportunity to clarify once and for all that courts do not owe deference to Commission commentary that expands the Sentencing Guidelines.

Cardiovascular Safety Pharmacology: Best Practice Considerations for the In Vivo QTc Core Assay, Upcoming Webinar Hosted by Xtalks

Wednesday, November 24, 2021 - 1:30pm

ICH guidelines provide information regarding best practices when designing and executing preclinical safety pharmacology studies.

Key Points: 
  • ICH guidelines provide information regarding best practices when designing and executing preclinical safety pharmacology studies.
  • The in vivo QTc assay is used by the pharmaceutical industry to characterize the potential for delayed ventricular repolarization and is a core safety assay mentioned in ICH S7B guideline.
  • In the second segment of this webinar, they will discuss exposure-response (ER) analysis, or pharmacokinetic/pharmacodynamic (PK/PD) analysis of cardiovascular telemetry data.
  • For more information, or to register for this event, visit Cardiovascular Safety Pharmacology: Best Practice Considerations for the In Vivo QTc Core Assay.

Borderless Capital Closed a $10M PLANETS.Fund to Build Green Data Economy on Algorand

Tuesday, November 23, 2021 - 5:21pm

MIAMI, Nov. 23, 2021 /PRNewswire/ -- Borderless Capital, the Miami-based venture capital firm dedicated to the Algorand ecosystem, announced today the closing of PLANETS.Fund, a $10M fund focused on building a green data economy. The fund will invest in the ecosystem surrounding PlanetWatch, the world's first decentralized indoor and outdoor air quality monitoring network built on the Algorand blockchain. "PlanetWatchers" or Air quality sensor hosts participating in the PlanetWatch network are compensated with PLANETS tokens for streaming air quality data. The PLANETS.Fund is planning to invest the raised capital to deploy a global network of thousands of PlanetWatch air quality sensors across the globe. The Fund will also hold a long term position in PLANETS tokens and equity.

Key Points: 
  • MIAMI, Nov. 23, 2021 /PRNewswire/ -- Borderless Capital , the Miami-based venture capital firm dedicated to the Algorand ecosystem, announced today the closing of PLANETS.Fund, a $10M fund focused on building a green data economy.
  • "PlanetWatchers" or Air quality sensor hosts participating in the PlanetWatch network are compensated with PLANETS tokens for streaming air quality data.
  • The PLANETS.Fund is planning to invest the raised capital to deploy a global network of thousands of PlanetWatch air quality sensors across the globe.
  • Borderless Capital is a modern financial institution investing capital and co-building financial products that accelerate access, bootstrap adoption, and create value globally through the Algorand Borderless Economy.

Borderless Capital Closed a $10M PLANETS.Fund to Build Green Data Economy on Algorand

Tuesday, November 23, 2021 - 5:21pm

MIAMI, Nov. 23, 2021 /PRNewswire/ -- Borderless Capital, the Miami-based venture capital firm dedicated to the Algorand ecosystem, announced today the closing of PLANETS.Fund, a $10M fund focused on building a green data economy. The fund will invest in the ecosystem surrounding PlanetWatch, the world's first decentralized indoor and outdoor air quality monitoring network built on the Algorand blockchain. "PlanetWatchers" or Air quality sensor hosts participating in the PlanetWatch network are compensated with PLANETS tokens for streaming air quality data. The PLANETS.Fund is planning to invest the raised capital to deploy a global network of thousands of PlanetWatch air quality sensors across the globe. The Fund will also hold a long term position in PLANETS tokens and equity.

Key Points: 
  • MIAMI, Nov. 23, 2021 /PRNewswire/ -- Borderless Capital , the Miami-based venture capital firm dedicated to the Algorand ecosystem, announced today the closing of PLANETS.Fund, a $10M fund focused on building a green data economy.
  • "PlanetWatchers" or Air quality sensor hosts participating in the PlanetWatch network are compensated with PLANETS tokens for streaming air quality data.
  • The PLANETS.Fund is planning to invest the raised capital to deploy a global network of thousands of PlanetWatch air quality sensors across the globe.
  • Borderless Capital is a modern financial institution investing capital and co-building financial products that accelerate access, bootstrap adoption, and create value globally through the Algorand Borderless Economy.

Considering the Impact of the Coronavirus, the New Moving Forward with COVID-19 Kinesiology Guidelines Addresses Cardiorespiratory Health

Monday, November 22, 2021 - 12:00pm

Through the MOVING FORWARD WITH COVID-19 KINESIOLOGY GUIDELINES FOR MAINTAINING OPTIMAL HEALTH, CKA demonstrates how Kinesiologists are part of the solution to support Canadians on the road to recovery.

Key Points: 
  • Through the MOVING FORWARD WITH COVID-19 KINESIOLOGY GUIDELINES FOR MAINTAINING OPTIMAL HEALTH, CKA demonstrates how Kinesiologists are part of the solution to support Canadians on the road to recovery.
  • The Guidelines focus on six fields of practice where the expertise of Kinesiologists can help: cardiorespiratory health, cognitive capacities including mental health, ergonomics, functional abilities, weight gain and obesity, and safe return to sport.
  • Shortness of breath, chest pain, trouble breathing, feeling dizzy or frequent coughing can all be signs of potential heart and respiratory problems.
  • In Canada, heart disease is the second leading cause of death after cancer, and a leading cause of hospitalization.